Browse MYO5B

Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF01843 DIL domain
PF00612 IQ calmodulin-binding motif
PF00063 Myosin head (motor domain)
Function

May be involved in vesicular trafficking via its association with the CART complex. The CART complex is necessary for efficient transferrin receptor recycling but not for EGFR degradation. Required in a complex with RAB11A and RAB11FIP2 for the transport of NPC1L1 to the plasma membrane. Together with RAB11A participates in CFTR trafficking to the plasma membrane and TF (transferrin) recycling in nonpolarized cells. Together with RAB11A and RAB8A participates in epithelial cell polarization. Together with RAB25 regulates transcytosis.

> Gene Ontology
 
Biological Process GO:0003014 renal system process
GO:0003091 renal water homeostasis
GO:0030104 water homeostasis
GO:0032439 endosome localization
GO:0048871 multicellular organismal homeostasis
GO:0050878 regulation of body fluid levels
GO:0050891 multicellular organismal water homeostasis
GO:0051640 organelle localization
Molecular Function GO:0000146 microfilament motor activity
GO:0003774 motor activity
GO:0003779 actin binding
GO:0005516 calmodulin binding
GO:0017016 Ras GTPase binding
GO:0017137 Rab GTPase binding
GO:0031267 small GTPase binding
GO:0051020 GTPase binding
Cellular Component GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0030659 cytoplasmic vesicle membrane
GO:0044448 cell cortex part
GO:0045177 apical part of cell
GO:0045179 apical cortex
GO:0055037 recycling endosome
GO:0099568 cytoplasmic region
GO:0099738 cell cortex region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-445717: Aquaporin-mediated transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-432040: Vasopressin regulates renal water homeostasis via Aquaporins
Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYO5B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYO5B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYO5B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.0340.0264
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9880.266
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.0740.12
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.70.165
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3060.889
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2010.673
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.910.109
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.3230.286
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5670.654
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3040.778
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.2560.463
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3890.00971
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYO5B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.25.516.70.0222
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.26.815.40.0651
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.811.8120.427
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.118.24.91
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.27.45.80.69
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYO5B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYO5B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYO5B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYO5B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYO5B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYO5B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYO5B
Namemyosin VB
Aliases KIAA1119; MYO5B variant protein; myosin-Vb; Unconventional myosin-Vb
Chromosomal Location18q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYO5B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.